ARYx Therapeutics, Inc. (ARYX)

Market Cap	33.00
Revenue (ttm)	n/a
Net Income (ttm)	-18.33M
Shares Out	33.46M
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,090
Average Volume	94,348
Open	0.0000
Previous Close	0.0000
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 0.0000
Beta	508.39
RSI	41.95
Earnings Date	n/a

About ARYx Therapeutics

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 56
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARYX